Welcome Syfon,
I think you will find being a member of SI a good investment in your time and money. I'm glad you have chosen to visit this thread.
As for TTNP:
I had a very informative and positive telephone conversation with a company official this afternoon. At the conclusion of our talk, I had a better feel for the potential in this stock. As mentioned earlier, timing is very important in investing in biotechs, and Titan is no different. It will take news, but more important results for the stock to move, therefore, I'm looking at a longterm investment in TTNP and not a short term play. However, when the train leaves the station it behooves you to be on board.
The bottom line for TTNP is that they aren't a "one horse" show. For such a small market cap stock they have a very diverse potential product line. For example they have the following:
1) ILOPERIDONE---for the treatment of schizophrenia and related disorders. It is obvious that Novartis has a commitment for this drug, mainly because they are losing market share with their current drug for this disease. It appears that Novartis plans to expand their Phase III trial, which indicates to me that they expect to capture more than the originally projected 10% of this market.
2) SPERAMINE- for the treatment of Parkinson's disease. Preclinicals are very positive in monkey trials.
3) In my original post for this thread, I gave little attention to the cancer therapeutic vaccines that Titan is working on. The first vaccine is CeaVac, a glycoprotein present on the surface of colon, stomach and pancreatic cancer cells. Injections of CeaVac are intended to induce an antibody response from the patients immune system against cancer cells expressing CEA.
The next two vaccines are, TriGem and TriAB, for the treatment of small cell lung cancer and breast cancer. In Phase I trials they were proven to be safe for human use.
For each of these above mentioned vaccines it is expected that they will enter Phase II trials with the next few months and possibly within the next month.
PIVANEX is another drug under development by Titan. PIVANEX is an injectable small molecule drug intended to treat various types of solid tumors. It is expected that Phase II trials will begin in the very near future.
Currently Titan has funds to carry them through the next two years. With the potential for a major partnership with any or all four of the drugs mentioned above, and currently with major support from Novartis, IMO Titan has a very bright future. |
